National cohort study on renal and systemic thrombotic microangiopathy
French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"
This study is trying to understand rare diseases that cause blood clots and kidney problems in adults to find better ways to diagnose and treat them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Tours Academic / other |
| Locations | 1 site (Tours) |
| Trial ID | NCT05991245 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate thrombotic microangiopathies (TMAs), a rare group of diseases that can lead to serious renal and systemic complications. By collecting data from over 20 centers over a period of more than 10 years, the study seeks to clarify the pathophysiology, optimal management, and prognosis of TMAs, particularly focusing on the differences between renal-limited and systemic TMAs. The study will include adult patients who have undergone renal biopsies for impaired renal function and will analyze various clinical parameters to better understand the disease's impact. The goal is to improve diagnostic workups and patient outcomes through comprehensive data collection and analysis.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have undergone renal biopsy for impaired renal function and exhibit symptoms of systemic thrombotic microangiopathy.
Not a fit: Patients who have undergone kidney transplantation will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and management strategies for patients suffering from thrombotic microangiopathies.
How similar studies have performed: While there have been studies on thrombotic microangiopathies, this multicenter approach with a focus on comprehensive diagnostic workups is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult patients 18 years of age or older 2. Who have undergone renal biopsy of the native kidney for impaired renal function between 2009 and July 2022. 3. Presence of classically defined systemic MAT (most of the following parameters: elevated LDH, decreased haptoglobin, schizocytes, thrombocytopenia and anemia) AND/OR presence of arteriolar or glomerular renal MAT as indicated by the pathologist (including endothelial turgor, mesangiolysis, double contours, presence of thrombi, fibrinoid necrosis of the arterial wall). Exclusion Criteria: 1. Kidney transplantation
Where this trial is running
Tours
- Department of Nephrology, University Hospital of Tours — Tours, France (Recruiting)
Study contacts
- Principal investigator: Valentin Maisons, MD — CHRU TOURS, Nephrology
- Study coordinator: Jean-Michel Halimi, MD, PhD
- Email: jmhalimi@univ-tours.fr
- Phone: 02.47.47.37.46
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.